AMPK phosphorylation attenuated hepatic steatosis and fatty liver disease, etc., by inhibiting the expression of SREBP1, and further the inhibition of ACC and FASN (Li et al., 2011; Lee et al., 2015; Dihingia et al., 2018). Here, SREBF1 is linked to fatty liver disease.